Prostate tumors are among the most heterogeneous of cancers, both histologically and clinically. Microarray expression analysis was used to determine whether global biological differences underlie common pathological features of prostate cancer and to identify genes that might anticipate the clinical behavior of this disease. While no expression correlates of age, serum prostate specific antigen (PSA), and measures of local invasion were found, a set of genes was identified that strongly correlated with the state of tumor differentiation as measured by Gleason score. Moreover, a model using gene expression data alone accurately predicted patient outcome following prostatectomy. These results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis.
Copyright © 2002 Cell Press.
Cancer Cell, Vol 1, 203-209, March 2002
Report
Gene expression correlates of clinical prostate cancer behavior
1Department of Adult Oncology, Boston, MA 02115 USA
2Department of Pediatric Oncology, Boston, MA 02115 USA
3Department of Biostatistical Sciences, Dana-Farber Cancer Institute, Boston, MA 02115 USA
4Department of Internal Medicine, Boston, MA 02115 USA
5Department of Surgery/Urology, Boston, MA 02115 USA
6Department of Pathology, Boston, MA 02115 USA
7Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 USA
8Whitehead Institute/Massachusetts Institute of Technology, Center for Genome Research, Cambridge, MA 02139 USA
9Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139 USA
10Pharmaceutical Research Institute, Bristol-Myers Squibb, Inc., Princeton, NJ 08543 USA
Corresponding author
Phil Febbo
phil_febbo@dfci.harvard.edu
and William Sellers
william_sellers@dfci.harvard.edu
Summary
Footnotes
12These authors contributed equally14Present address: Baptist Hospital of Miami, Miami, Florida 3317613These authors codirected this work
Articles that cite this article
- A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer
Justin Lamb, Sridhar Ramaswamy, Heide L. Ford, Bernardo Contreras, Robert V. Martinez, Frances S. Kittrell, Cynthia A. Zahnow, Nick Patterson, Todd R. Golub and Mark E. Ewen
Cell, 2003, 114:3:323-334[Summary] [Full Text] [PDF] [Supplemental Data] - The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer
Edgard Graner, Dan Tang, Sabrina Rossi, Antonella Baron, Toshiro Migita, Lisa J. Weinstein, Mirna Lechpammer, Dieter Huesken, Johann Zimmermann, Sabina Signoretti and Massimo Loda
Cancer Cell, 2004, 5:3:253-261[Summary] [Full Text] [PDF] - Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
Kun Ping Lu
Cancer Cell, 2003, 4:3:175-180[Full Text] [PDF] - Myc-driven murine prostate cancer shares molecular features with human prostate tumors
Katharine Ellwood-Yen, Thomas G. Graeber, John Wongvipat, M. Luisa Iruela-Arispe, JianFeng Zhang, Robert Matusik, George V. Thomas and Charles L. Sawyers
Cancer Cell, 2003, 4:3:223-238[Summary] [Full Text] [PDF] [Supplemental Data] - Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Scott A. Armstrong, Andrew L. Kung, Meghann E. Mabon, Lewis B. Silverman, Ronald W. Stam, Monique L. Den Boer, Rob Pieters, John H. Kersey, Stephen E. Sallan, Jonathan A. Fletcher, Todd R. Golub, James D. Griffin and Stanley J. Korsmeyer
Cancer Cell, 2003, 3:2:173-183[Summary] [Full Text] [PDF] - The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer?
William R. Sellers and Massimo Loda
Cancer Cell, 2002, 2:5:349-350[Summary] [Full Text] [PDF] - Optimal gene expression analysis by microarrays
Lance D. Miller, Philip M. Long, Limsoon Wong, Sayan Mukherjee, Lisa M. McShane and Edison T. Liu
Cancer Cell, 2002, 2:5:353-361[Summary] [Full Text] [PDF] [Supplemental Data] - Focus on prostate cancer
William Isaacs, Angelo De Marzo and William G. Nelson
Cancer Cell, 2002, 2:2:113-116[Full Text] [PDF] - Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
Sooryanarayana Varambally, Jianjun Yu, Bharathi Laxman, Daniel R. Rhodes, Rohit Mehra, Scott A. Tomlins, Rajal B. Shah, Uma Chandran, Federico A. Monzon, Michael J. Becich, John T. Wei, Kenneth J. Pienta, Debashis Ghosh, Mark A. Rubin and Arul M. Chinnaiyan
Cancer Cell, 2005, 8:5:393-406[Summary] [Full Text] [PDF] [Supplemental Data] - A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity
Ingrid G.M. Kolfschoten, Bart van Leeuwen, Katrien Berns, Jasper Mullenders, Roderick L. Beijersbergen, Rene Bernards, P. Mathijs Voorhoeve and Reuven Agami
Cell, 2005, 121:6:849-858[Summary] [Full Text] [PDF] [Supplemental Data]
